- Home
- BBOT
as 11-14-2025 3:37pm EST
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 902.8M | IPO Year: | N/A |
| Target Price: | $24.75 | AVG Volume (30 days): | 134.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.70 - $13.68 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BridgeBio Oncology Therapeutics Inc. Common Stock News
BBOT Breaking Stock News: Dive into BBOT Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
GlobeNewswire
a month ago
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Compare BBOT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBOT BridgeBio Oncology Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.